Members can serve more than one term, and although there are no formal rules dictating the length of time members can serve on the Committee, historically members c-Met inhibitor serve no more than two terms (i.e., 4 years). Representatives of the affiliated organizations nominate candidates and forward their names to the KCDC Director for review. The list of nominees is then sent to the Health Minister, who makes the final selection. All members are given an official appointment letter. When a person joins the KACIP, he or she must sign a declaration of confidentiality. Members have an obligation to notify the Committee if they have any business with a vaccine producer

(e.g., as KPT-330 concentration a consultant) and, if so, they must resign from the Committee. They must also report to the KCDC if they own any stock in vaccine companies, recluse themselves from voting on an issue with which they are personally involved or if they are stockholders in a vaccine company, and avoid interviews with the press if relevant officials are not present. Members are given an allowance for travel expenses to attend the

meetings. Members have an obligation to attend every meeting – baring emergencies – and may be dismissed if they miss two meetings in a row without giving a reason. In addition to these members, external experts, such as principal investigators of vaccine clinical trials, KFDA officials involved

in vaccine licensure, and more rarely, scientists from vaccine companies, may be asked to participate in certain meetings as ex-officio members to lend their expertise on a particular crotamiton topic. These experts cannot, however, participate in decision-making. According to the written rules governing the KACIP in the Prevention of Contagious Diseases Act, the Committee must meet at least four times a year, and additional meetings can be held, as needed, upon the request of the Minister of Health or more than half of the Committee members, with approval by the Chairperson. In 2009, for example, a total of eight meetings were held, many to discuss planning for the introduction of a vaccine against the new H1N1 strain of influenza. The Director of the Division of VPD Control and the NIP sets up the agenda for each meeting, based on suggestions from KACIP members, KCDC staff, other experts and ex-officio members, and members of KACIP sub-committees (described below). The decision to add a topic, such as the introduction of a new vaccine, to the KACIP agenda can be prompted by the licensure of a new vaccine by the KFDA for use in the private sector, the declaration of a new goal by the World Health Organization (see Section 7), an outbreak or increase in incidence of a VPD, or when specific issues related to a vaccine arise (such as reports of adverse events).